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Vancomycin is a glycopeptide antibiotic employed in the treatment of infections caused by certain methicillin-resistant staphylococci.
It is indicated also for patients allergic to penicillin or when there is no response to penicillins or cephalosporins. The adequate
vancomycin concentration levels in blood serum lies between 5 and 10 mg/L. Higher values are toxic, causing mainly nephrotoxicity
and ototoxicity. Various analytical methods are described in the literature: spectrophotometric, immunologic, biologic and
chromatographic methods. This paper reviews the main analytical methods for vancomycin determination in biological fluids and
in pharmaceutical preparations.
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INTRODUCTION
Vancomycin is a glycopeptide antibiotic first isolated in 1956 from
Streptomyces orientalis cultures in a research developed by Laboratory
Lilly, USA. It was first introduced in medical clinic in 1958.
The structure of vancomycin (Figure 1), elucidated at the end
of the 70’s, is tricyclic and the molecular mass was about 1500 Da.
Vancomycin acts against gram-positive coccus and bacillus inhibiting
the biosynthesis of the cell-wall mucopeptide, leading to a growth
stalling and to the eventual destruction of the cell by lysis, in addition
to which, RNA synthesis is inhibited. Vancomycin is resistant to
the proteolytic enzymes activity due to its molecule complexity1-3.
The discovery of vancomycin represented, at first, an alternative
for treating infections caused by the staphylococcus that produces
penicilinase and the ones that are resistant to penicillin G. However,
the discovery of methicillin, oxacillin and other isoxazolilpenicillins
lessened the therapeutical importance of vancomycin due to its
higher toxicity3.
Nowadays, however, vancomycin has emerged as an important
anti-infectious agent as a consequence of the discovery of methicillin
resistant staphylococcus and also due to infections caused by
Clostridium difficile.
Vancomycin is very efficient against a number of gram-positive
micro-organisms, including Staphylococcus aureus and Staphylococcus
epidermidis. It is also the chosen antibiotic to treat bacterial infections
in patients allergic to β-lactam antibiotics. Today, vancomycin resistant
Staphylococcus aureus strains are a serious concern4-6.
Ototoxicity, that damages the auditive nerve, is the major
problem caused by vancomycin treatment, as well as nephrotoxicity.
The ototoxicity occurs in 2 to 5.5% of the patients, more frequently
when blood concentration levels exceed 80 mg L-1. The
nephrotoxicity is observed in 5 to 7% of the patients and is more
likely to occur when the serum vancomycin concentration exceeds
10 mg L-1. This percentage can reach 35%, if the vancomycin is
associated with aminoglycoside drugs. “Red-man” syndrome, also
known as “red-neck” syndrome is reported to occur in up to 47% of
patients receiving vancomycin. The reaction is characterized by face,
neck, and upper extremities erythematous flushing, and it is thought
to be related to histamine release in response to a too-rapid infusion.
Thrombophlebitis, fever, rash and neutropenia occur at lower rates7,8.
It is recommended intravenous administration. Vancomycin is
not absorbed orally and intramuscular administration can provoke
pain, hypersensitivity and muscular tissue necrosis. For the majority
of gram-positive micro-organism treatments, the proper vancomycin
seric concentration lies in a 5 to 10 mg L-1 range. Higher values are
considered potentially toxic7 and, therefore, it is recommended to
maintain the seric concentration below 40 mgL-1 to avoid or, at least,
reduce, the toxic effects9. However, there are several controversies
when it comes to turn serum vancomicyn concentration a routine.
Generally, for adults with normal renal functions, a daily monitoring
is not considered necessary. Instability of vancomycin concentration
in renal failure, renal support therapies, obesity, liver failure,
neutropenia, malignancy and sepsis demands closer monitoring. It
is also recommended for patients with altered renal function,
specially for those with therapy combined with other aminoglycoside
or other nephrotoxic drug; to maintain the adequate concentration
for patients under renal dialysis; for those with altered distribution
Figure 1. Structural formula of vancomycin
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volume, i.e., with burnings; infants and newly born babies; pregnant
women; patients with cancer; those who need high doses of antibiotic
and instances of prolonged vancomycin treatment7, 10, 11.
Therefore, it is really necessary to determinate blood vancomycin
concentration, as well as in other body fluids, in order to adjust its
correct dose, for better results with minor side effects. To adequately
control its concentration in biological fluids, it is obviously necessary
to quantitatively analyze its amounts in the pharmaceutical dosage forms.
A review of the quantitative analytical methods, described in
the literature for vancomycin determination, both in biological
matrixes and in pharmaceutical products, is presented below.
SPECTROPHOTOMETRIC METHODS
Fooks et al.12 developed a colorimetric method for vancomycin
quantitative analysis, based on the reaction of Folin-Ciocalteau’s reagent
with antibiotic’s phenolic groups, giving rise to a colored compound
possessing the maximum absorption at 725 nm. However, this reagent
is not specific for vancomycin and it gives rise to blue color with other
substances, mainly with those presenting the phenolic group13.
El-Ashry et al.14 described a determination method for some
phenolic antibiotics (vancomycin, cefadroxil and amoxicillin), based
on measurement of the orange-yellow species produced when these
drugs are coupled with diazotized benzocaine in triethylamine
medium. The stoichiometric ratio for the studied compounds was
found to be 1:1. The method is applicable over the range of 2-18 μg
mL-1 for vancomycin. The formed compound absorbs at 442 nm and
the detection limit is 0.0156 μg for vancomycin.
Belal et al.15 described a method that involves a prior treatment
with nitrous acid, then measuring the formed nitroso derivative,
either by spectrophotometry or polarography. The calibration plot
of the photometric method is linear over the range of 4-32 μg mL-1,
with minimum detectability of 2.7 μg mL-1 (1.8×10-6 mol L-1).
Three methods were proposed by Sastry et al.16, based on
vancomycin oxidation with a sodium metaperiodate excess, forming
colored species, after reacting with different substances. Though,
with good analytical results (detection limit 1.15 to 5.11 of μg mL-1),
in all of those methods, it is necessary to heat the substances for
about 40 min in a boiling water bath. However, despite the known
fact that vancomycin has its degradation rate increased when heated
in solution, these methods seem not to be affected by heating17,18.
Spectrophotometric analytical methods are usually of low cost
and relatively easy to be performed, but probably due to the
complexity of the vancomycin molecule, very few methods using
such technique are described in the literature. Due to the insufficient
detection limit, the related spectrophotometric procedures for
vancomycin are adequate only for the analysis of medicines and not
to determine antibiotics in biological fluids.
IMMUNOLOGIC METHODS
The immunologic methods employed in vancomycin quanti-
fication include the following techniques: fluorescence polarization
immunoassay (FPIA), radioimmunoassay (RIA) and enzyme-
multiplied immunoassay (EMIT). The quantification of vancomycin
using FPIA and EMIT19-23 are analytical techniques based on
commercial kits or automated analyzers. These procedures offer
sensitivity, sensibility, quickness, and reduced human contact with
the biological samples. However, there is the disadvantage of always
having to depend on the companies that hold commercial rights.
The FPIA technique has been pointed out as being the most
employed one for routine analysis of vancomycin in biological
samples7. Tobin et al.9 related that it was used in 97% of the hospitals
investigated. The EMIT is another useful clinical assay with simi-
lar results when compared whit FPIA and HPLC 24.
However, it is considered to overestimate the amount of
vancomycin in blood samples, compared to FPIA and HPLC
techniques. This could be a consequence, among other factors, of
the interference of crystalline degradation products17, 24-32.
Considering that, Abbot Laboratories developed the kit “AxSYM
Vancomycin II Assayâ”, for vancomycin quantification with FPIA. The
assay demonstrates no cross-reactivity to crystalline degradation product
in commonly-prescribed and over-the-counter drugs, as well as a
minimum interference from endogenous substances. Linearity of the
calibration curve from 1.0 to 100 µg mL-1 was observed. The variation
coefficients range from about 2.9 to 4.3%. The sensitivity is lower than
2.0 µg mL-1. A good correlation with other methods was observed22,33.
The RIA method34-37 had also been employed. Despite the good
quality of the analytical results, it is less efficient and more expensive
than FPIA, and there is also the disadvantage of using
radioactive substances37.
BIOLOGICAL METHODS
Antibiotics quantification using micro-organisms can be performed
by the disk diffusion technique and by turbidimetry. A linear relationship
between zone diameter and concentration was obtained.
The most used method is the disk diffusion technique, that
correlates the size of the zone were the growing was inhibited with
the substance dose. A linear relationship between zone diameter
and antibiotic concentration was obtained.
However, when the substance is chemically well defined and
its quantification is possible through the physico-chemical properties,
biological methods are not the first choice38. Despite the low cost,
they are usually very slow and involve intense laboratorial work,
when compared to other methods21,34.
In biological assays for vancomycin quantification by disk
diffusion technique, Bacillus subtilis ATCC 663321,34,39 or Bacillus
subtillis W23 40 are generally employed as reference micro-
organisms. However, Durodie and Coleman41 presented a new
technique, using Streptococcus sanguis ATCC 12396 to increase
the detection range of vancomycin, that is between 1 and 16 mg
mL-1 when Bacillus subtillis is used.
When using biological methods, the analysis time may vary,
depending on the procedure used: from six to eight hours at 37
oC21,34; from ten to twelve at 35 – 37 oC40,41, and from sixteen to
eighteen at 35 – 37 oC39,42. Also, there is not good sensibility and
reproducibility. Therefore, these methods for the quantification of
vancomycin in a routine method are not used nowadays.
CHROMATOGRAPHIC METHODS
The initial chromatographic analysis of vancomycin was
performed on paper and used for identification purposes43,44. For
separation and identification of vancomycin thin-layer chroma-
tography, normal and reverse phases, were used45. Today, the HPLC
is the most used technique for the vancomycin analysis, being also
official method (United States Pharmacopoeia46 and British
Pharmacopoeia47) for purity determination.
In pharmaceutical industries, the use of HPLC has been
associated to the antibiotics analysis and this technology became
available for quality control. In the clinical laboratory the use of
this technique has been efficient for analytes determination of in
several biologic fluids. Therefore, HPLC technique has been
developed for the analysis of vancomycin in medicines48-52, as well
as for the determination in biological fluids25,26,53-67.
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Table 1. Methods for quantification of vancomycin in biological and in pharmaceutical matrixes
Method Detection system LOD Matrices Ref.
HPLC UV, λ= 240 nm 0.01 μg mL-1 Human plasma 55
HPLC Tanden mass spectrometry 1.0 ng mL-1 Dog, rat and primate serum and urine 66
HPLC Tandem mass spectrometry 0.007 μg mL-1 Rat plasma 65
HPLC UV, λ= 235 nm — Human serum 25
HPLC Electrochemical 0.5 μg mL-1 Human plasma 62
HPLC UV, λ= 282 nm 0.5 μg mL-1 Human plasma and tissues 60
HPLC UV, λ= 214 nm 100 ng mL-1 Human serum, cerebrospinal 53
fluid and peritoneal fluid
HPLC UV, λ= 230 nm — Pharmaceuticals forms 52
HPLC UV, λ= 225 nm 0.32 μg mL-1 Human serum and plasma 57
HPLC UV, λ= 198 nm 0.03 μg mL-1 Rabbit serum, vitreous and aqueous humor 59
HPLC UV, λ= 240 nm 0.4 μg mL-1 Microdiaysate and human plasma 67
HPLC UV, λ= 230 nm 30.0 ng mL-1 Influenza vaccine 50
HPLC UV, λ= 230 nm 0.5 μg mL-1 Human plasma 63
HPLC UV, λ= 225 nm — Antibiotics mixture 48
HPLC UV, λ= 254 nm — Vancomycin mixtures and related substances 49
HPLC UV, λ= 228 nm 1.0 μg mL-1 Human serum 56
HPLC UV, λ= 229 nm 1.0 μg mL-1 Human serum and tissues 54
HPLC UV, λ= 229 nm 0.2 μg mL-1 Human plasma 58
HPLC UV, λ= 280 nm —- Pharmaceuticals forms and impurities 51
HPLC UV, λ= 230 nm 0.8 μg mL-1 Human plasma 61
HPLC UV, λ= 215 nm 0.5 mμg mL-1 Human plasma 64
HPLC UV, λ= 280 nm —- Human plasma 26
Spectrophotometric UV, λ = 725 nm —- Pharmaceuticals forms 12
Spectrophotometric UV, λ = 725 nm 0.0156 μg mL-1 Pharmaceuticals forms 14
Polarography Electrode graphite 2.4´10–2 molL-1 Pharmaceuticals forms 15
rod and Ag/AgCl
Spectrophotometric UV, λ = 240 nm 2.7 μg mL-1 Pharmaceuticals forms 15
Spectrophotometric UV, λ = 620 nm 1.15 ×10–2 μg mL-1 Pharmaceuticals forms 16
Spectrophotometric UV, λ = 520 nm 5.0 ×10–2 μg mL-1 Pharmaceuticals forms 16
Spectrophotometric UV, λ = 5400 nm 5.0 ×10–2 μg mL-1 Pharmaceuticals forms 16
Capillary Laser-induced 1.0 μg mL-1 Human plasma 68
electrophoresis fluorescence
FIA Amperometric —- Pharmaceuticals forms 69
Capillary Laser-induced 0.98 ng mL-1 Human plasma 71
electrophoresis fluorescence
Mass spectrometry with 1.0 ng mL-1 Human serum 70
pyrolysis inlet system
Disk diffusion35 Bacillus subtilis < 0.8 μg mL-1 Human serum 40
ºC/10-12 h W23
Disk diffusion37 Bacillus subtilis —- Human serum 42
ºC/18 h ATCC6633
Disk diffusion35 Streptococcus sanguis 0.25 mg L-1 Human serum 41
ºC/12 h ATCC12396
Disk diffusion35 Bacillus subtilis ≤ 25 μg mL-1 Human serum 39
ºC/16-18 h ATCC6633
Disk diffusion37 Bacillus subtilis —- Human serum 21
ºC/6 h ATCC6633
Disk diffusion37 Bacillus subtilis —- Human serum 34
ºC/8 h ATCC6633
RIA Scintillation counter, γ-rays —- Human serum 34
RIA Scintillation counter, γ-rays 0.5 μg mL-1 Human serum 36
RIA Scintillation counter, γ-rays —- Human serum 37
RIA scintillation counter, γ-rays 0.8 μg mL-1 Human serum and urine 35
EMIT UV, λ= 340 nm —- Human serum 19
EMIT UV —- Human serum 20
FPIA UV,fluorescence —- Human serum 21
FPIA UV,fluorescence —- Human serum 22
FPIA UV,fluorescence —- Human serum 23
FPIA UV,fluorescence < 2.0μg mL-1 Human serum 33
RIA - Radioimmunoassay; EMIT - Enzyme multiplied immunoassay technique; FPIA - Fluorescence polarization immunoassay; FIA -
Flow injection analysis; HPLC - High performance liquid chromatography.
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Generally, it was observed that the majority of the applied
methods in the determination of vancomycin with HPLC use UV
detectors, working in a wavelength range from 198 nm59 to 282
nm60. Few works employ other kind of detectors, for example, Favetta
et al.62 use an electrochemical detector and Shibata et al.65 employ
mass spectrometry for the detection.
It can be also noted that the use of a C
18
 column is the most
common option, associated with a variety of mobile phases. When
the HPLC technique is used for the determination of vancomycin in
biological fluids, the extraction procedure of the analyte is done
based on chemical processes, involving protein precipitation and
use of organic solvents. In some methods, however, the extraction
process is associated to the chromatography as continuous
systems56,59,66. Recently analytical techniques, where the samples
are injected without treatment, have been developed. Kitahashi and
Furuta68 developed an assay for measuring vancomycin concentration
by micellar electrokinetic capillary chromatography with detection
at 210 nm using direct serum injection. The migration time of
vancomycin was about 7 minutes. The linearity was from 0 to
100 μg mL-1 and the limit of detection was 1.0 μg mL-1. No observed
interference from 32 other antibiotics was observed.
Shibata et al.65 described a novel high-performance liquid
chromatography tandem mass spectrometry method for determination
of vancomycin in serum and urine without treatment. After the
addition of internal standard, serum and urine samples were directly
injected into a HPLC system consisting of an extraction column and
dual analytical columns. The columns are connected through two
switching valves.
OTHER METHODS
Chabenat et al.69 proposed the use of the complex formed
between copper(II) and vancomycin for the determination of this
antibiotic, in continuous flux and amperometric detection.
Mass spectrometry coupled with a pyrolysis inlet system was
compared with HPLC for vancomycin determination and its crystal
degradation products in human serum. Quantitative analysis was
performed by selected ion monitoring method at 108 mass/charge
(m/z) of the pyrolysis product of vancomycin. The detection limit of
the method was 1 ng mL-1; the linearity was observed between 1 ng
mL-1 and 10 mg mL-1; the relative standard deviation was 1%; the
time of analysis was 30 min and sample volume 50 µL. These results
are far better than those of the HPLC method. However the authors
related that the HPLC method can individually determine the
concentration of vancomycin and its degradation products70.
A competitive immunoassay using capillary electrophoresis
with laser-induced fluorescence for vancomycin was developed.
Capillary electrophoresis using a tris-glycine running buffer
provided adequate separation of antibody-bound from the unbound
fluorescent probe (tracer) in less than 4 min. Laser-induced-
fluorescence polarization provided high sensibility detection and
simultaneous monitoring of fluorescence intensity and polarization.
A fluorescence polarization value of 0.30 confirmed the formation
of the antibody-tracer complex. Calibration curves showed a
working linear range of 2–3 orders of magnitude with a minimum
detectable concentration of  0.98 ng mL–1 71.
CONCLUSION
As usual in quantitative analysis, the choice of the analytical
method to be employed for the vancomycin analysis will be always
dependent of several parameters that must be considered in each case:
the analytical matrix; the sample and aliquot sizes; reagents, apparatus
and trained personnel available; cost of the analysis; precision and
accuracy; time required for the complete analytical procedure.
Table 1 presents a summary of suggested methods in the analytical
literature for the quantitative analysis of vancomycin in several matrices.
It can be easily observed that HPLC is the preferred method either for
the analysis in biological or pharmaceutical material. However, for
the routine analysis in hospitals, in serum or plasma, immunologic
methods are the most used7.9. Despite these methods present a relatively
high cost and possible interferences, they allow rapid results, exempt
pre treatment of the samples and are processed with automatic
apparatus. Comparing HPLC methods with the immunologic, it is
observed that the former presents better accuracy and precision but
higher analytical delay and involve pre extraction of the analyte. To
avoid the necessity of the pre treatment some HPLC with direct
injection, using pre extraction columns, have been suggested54,66.
Biological assays are also used for vancomycin quantification,
inclusive in the last edition of the United States Pharmacopoeia47.
However they are not used for routine analysis if biological fluids
or medicines as they are slow, involve much laboratory work, present
low precision and accuracy and are non specific. In the case of
patients treated with more than one antibiotic the results can be
seriously affected.
HPLC have been also used for the analysis of medicines,
presenting detection limits as low as 1 ng mL-1. Spectrophotometric
detectors are the more frequently used despite the fact that the more
sensitive methods are those using mass detectors65.66.
The high specificity of the HPLC procedures allows the analysis of
vancomycin in presence of other substances in automated systems,
characteristics that justify the intense use of this technique in the analysis
of this antibiotic as it was also indicated, in a recent article, by Görög72.
The relatively recent use of capillary electrophoresis has been
observed. The results obtained with this technique are similar to
those obtained with HPLC but with lower cost.
The spectrophotometric methods are also used mainly due to the
low cost and operational simplicity. In the case of pharmaceutical
analysis the detection limits are comparable to those obtained with
HPLC. Their main disadvantage is the usual low specificity in presence
of similar chromophoric systems as those of the drug material.
Due to the complexity of the vancomicyn molecule and its size,
its quantitative analysis in biological matrixes and even in
pharmaceutical products can’t be considered a simple and cheap
matter. In our point of view, in face of the therapeutic importance of
this antibiotic and, of its toxic level, the development of new reliable
methods for vancomycin analysis, in various matrixes, must be rapid
and simple and, if possible, with low cost is necessary. Efforts must
be done in this direction. This opinion is reinforced if it is
remembered that, in a great part of the world, the financial sources
destined to the public health are so small that even for the antibiotic
acquisitions they are not always sufficient. Imagine how difficult it
is to use analytical and necessary procedures that demand expensive
devices and extremely specialized professionals.
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